You are here

products liability

What Laws Are Needed for the Internet of Things?

Jeff John Roberts, writing in GigaOM, writes about how we don't have rules yet to govern the Internet connections that have been brought to physical devices--the so-called "internet of things": "The first murder through the internet of things will likely take place in 2014, police service Europol warned this month. The crime could be carried out by a pacemaker, an insulin dosage device, a hacked brake pedal or myriad others objects that control life-and-death functions and are now connected to the internet." He notes that there are completely open questions on whether manufacturers of Internet-connected devices are going to face liability for privacy breaches: "In the future, judges may start asking if the concept of 'privacy by design' should become a safety standard, and even require internet companies to adopt the same pre-cautions as auto makers or playground designers."

Pfizer Wants to Limit Experts in Zoloft MDL

Hearings are being held in Philadelphia federal court this week on the admissibility of the testimony of plaintiffs' expert witnesses in litigation over whether Zoloft caused birth defects. The Legal Intelligencer's Sara Spencer (my former colleague) reports that drugmaker Pfizer is seeking to winnow out some of those experts. Both sides focused on a general causation expert, Dr. Anick Berard, The Legal reports. One defense lawyer said her position puts her "against the world."

Jury Awards $9 Bil. in First Actos Bellwether Trial

A federal jury awarded a $9 billion verdict in the first bellwether trial over whether Actos increases the risk of getting bladder cancer, The National Law Journal's Amanda Bronstad (and my current colleague) reports. U.S. District Judge Rebecca Doherty presided over the Louisiana federal trial. Eli Lilly & Co., which was found 25 percent liable, and Takeda Pharmaceuticals USA Inc., which was found 75 percent liable, are the defendants. Lilly co-promoted Actos with Takeda for several years.

Bronstad also reports that the jury awarded $1.475 million in compensatory damages and $9 billion in punitive damages: $6 billion against Takeda and $3 billion against Lilly. The high ratio between the compensatory and punitive damages is certainly going to invite a challenge.

Judge Denies Access to 'Misrepresentation' Evidence in Asbestos Bankruptcy

Submitted by Amaris Elliott-Engel on Sun, 03/30/2014 - 13:24

I'm writing several times a day about products liability for Law.com/The National Law Journal. Occasionally I cross-post a blog I find particularly interesting.

A bankruptcy judge, who found “demonstrable misrepresentation” by plaintiffs' lawyers in several asbestos cases, denied the motions of asbestos defendants and a media outlet to access that sealed evidence.

Ford Motor Co., joined by Volkswagen Group of America Inc, Honeywell International Inc. and Crane Co., filed a motion to unseal that evidence. In a separation motion, news outlet Legal Newsline sought to unseal the trial testimony and exhibits on which the judge based his Jan. 10, 2014, order, finding that plaintiffs' lawyers withheld evidence of their clients' exposure to other sources of asbestos in the bankruptcy case of Garlock Sealing Technologies, LLC.

Those cases included two that resulted in a $9 million verdict in California and a $1.35 million verdict in Texas, the judge said.

By denying the motions, U.S. Bankruptcy Judge George Hodges of the Western District of North Carolina said in a hearing on March 27 that he was hoping to “get all of us to an answer as simply as I can” on whether that evidence should be publicly accessible.

By denying the motions on their merits, the judge said he hoped that would get the motions to the U.S. district court on appeal for resolution at the same time.

Legal Newsline already has an appeal pending in the district court on being denied permission by Hodges to attend the hearing during which he heard evidence on the estimated liability Garlock faces for asbestos claims.

“The practical problem I have is this: if I granted the motions to unseal filed by Ford and Volkswagen and Legal Newsline it would essentially moot the appeal,” Hodges said.

Trevor Swett III, a plaintiffs attorney with Caplin & Drysdale, Chartered in Washington, argued that Hodges did not have subject-matter jurisdiction anymore because Legal Newsline has appealed the sealing of the evidence and the closing of the courtroom.

“They mean to unseal the evidence going to the supposed misrepresentation and suppression of evidence,” Swett argued. “That’s the same evidence implicated in their demands on appeal.”

Legal Newsline's attorney, Steven Pflaum, argued that jurisdiction was not divested because the district court only has to decide if the courtroom should have been closed during the estimation hearing.

Unsealing the evidence would allow public understanding of who has been victimized by a pattern of misrepresentation, said Pflaum, of Neal, Gerber & Eisenberg LLP in Chicago.

It is “vitally important that the public understand the courts,” Pflaum said.

Hodges ruled on a separate motion that insurer Aetna, Inc., and Rawling Company LLC, a cost containment vendor for insurers, brought to have access to Federal Rule of Bankruptcy 2019 statements. Those statements must be filed by anyone participating in bankruptcy cases.

Hodges said that social security numbers and the retention agreements law firms enter into with clients can't be disclosed.

“It appears to me ... that the interests of the opposing parties are not superior to the public rights to access and that there is a legitimate interest here on behalf of the movants” to protect their subrogation rights against asbestos defendants and reimbursement rights against members of insurance plans, Hodges said.



Read more: http://www.nationallawjournal.com/id=1202648736269/Judge-Denies-Access-t...

GM Detected Ignition Switch Problem Back in 2001

General Motors in the middle of a 1.6 million-strong recall involving faulty ignition switches. Now the carmaker says that it knew of faulty ignitiion switches back as early as 2001, which is three years earlier than previously reported, The Wall Street Journal reports. It's not just a recall that GM is facing: "GM's failure to act more quickly to remedy a defect that is now linked to accidents in which 12 people have lost their lives over the past decade has landed the company and new Chief Executive Mary Barra at the center of three different investigations—including a criminal probe," WSJ further reports.

Drug Companies Scaling Back Payments to Doctors for Drug Talks

Drug and medical-device companies are scaling back payments to doctors for promotional talks "as transparency increases and blockbuster drugs lose patent protection," ProPublica reports: "Eli Lilly and Co.’s payments to speakers dropped by 55 percent, from $47.9 million in 2011 to $21.6 million in 2012. Pfizer’s speaking payments fell 62 percent over the same period, from nearly $22 million to $8.3 million. And Novartis, the largest U.S. drug maker as measured by 2012 sales, spent 40 percent less on speakers that year than it did between October 2010 and September 2011, reducing payments from $24.8 million to $14.8 million."

The Physician Payment Sunshine Act, going to effect this year, is going to require all pharmaceutical and medical-device companies to publicly report payments to physicians, ProPublica reports.

Attorney Faces Second Loss in $600,000 Dispute with Clients Over Discovery Costs

Submitted by Amaris Elliott-Engel on Wed, 03/05/2014 - 17:23

I'm blogging several times a day about products liability for Law.com. Occasionally I cross-post an excerpt of a blog I find interesting:

The Mississippi Supreme Court has ruled against a plaintiffs' attorney for the second time in a dispute with two former clients over who owes money for discovery undertaken on the behalf of all plaintiffs in the massive federal diet-drug litigation.

Herbert Lee Jr. represented 13 plaintiffs who settled their claims that they were injured by taking diet drugs for around $32 million, according a recent opinion by Justice David Chandler. Lee agreed that six percent of the “gross amount of recovery” of each of his clients would be paid for the discovery materials generated in the diet-drug multidistrict litigation in the Eastern District of Pennsylvania.

Lee, however, billed the $1.92 million MDL fee to the plaintiffs. The federal court ordered one-third of all “common benefit fees” refunded.

Plaintiffs Gloria Thompson, who was paid $7.4 million in her settlement, and Deborah Dixon, who was paid $3.1 million, sued Lee, arguing that he had failed to refund their portion of the MDL fee and that his attorney fee exceeded their contingency agreements by 5 percent. Lee retained 45 percent of the MDL refund and refunded each of his 13 clients 1/13th of the remaining 55 percent.

When the case got to the Mississippi Supreme Court for the first time, the court upheld the plaintiff's victory in the trial court on the MDL fee. The Supreme Court said that the federal court required the MDL fee to be paid by attorneys and that Lee “erroneously had billed the MDL fee to his clients.”

During trial on remand, the jury found that Lee breached his 40 percent contingency fee contracts with his clients by charging them 45 percent. Still, the panel returned a verdict for Lee, finding that the plaintiffs had ratified a 45-percent fee by signing their settlements free from intimidation, coercion or fraud. Still, the trial judge determined that Lee owed plaintiff Thompson $420,000 and plaintiff Dixon $180,000 for the MDL fee.

During Lee's second appeal to the Mississippi Supreme Court, the court rejected Lee's arguments that the plaintiffs “fabricated that the original contingency-fee agreements provided for a 40-percent fee,” not a 45-percent fee as he claims. The plaintiffs contended at trial that Lee forged retainer agreements providing for a 45 percent fee.


 

Asbestos MDL Judge Advises Against Case Consolidation

Submitted by Amaris Elliott-Engel on Fri, 02/21/2014 - 13:36

I'm blogging several times a day about products liability for Law.com. Each day I cross-post an excerpt of the day's blog I find most interesting.

Mass torts cases must not be aggregated, and plaintiffs must provide facts to support their claims through expert reports, in order to avoid having nonmeritorious cases clogging the court process, says the federal judge presiding over the federal Asbestos Multidistrict Litigation for 5.5 years.

Asbestos MDL-875 has been the largest MDL in terms of claims and cases, wrote U.S. District Judge Eduardo C. Robreno in an article published in the Widener Law Journal.

The consolidation of large number of cases not only raises due process issues by forcing parties to litigate or settle cases in groups, but incentivizes “the number of cases that can be filed, not the relative merit of the individual case,” Robreno said.

Asbestos litigation has grown to over 186,000 cases and more than 10 million claims. Only 2,979 cases are still in the MDL.During his tenure presiding over the MDL, Robreno reported he decided 528 summary judgment motions, 59 issues of substantive state law, 16 issues of federal substantive law and 16 issues of federal procedural law.

Consolidating cases also did not work to resolve the MDL, Robreno said, adding it was an open question whether a national MDL was necessary to resolve the claims.

One of the reasons aggregations of cases did not work to resolve the cases was that class certification was rejected by the Third Circuit and then the U.S. Supreme Court, Robreno said. The first asbestos MDL judge, Judge Charles R. Weiner, tried to settle the claims of 250,000 to 2 million individuals who had been exposed to asbestos. The settlement was rejected on appeal because of the “Supreme Court's concerns over the manageability of such a mixed and large class, as well as the inability of the class mechanisms to deal with the issue of future claimants,” Robreno said. Federal legislative fixes also failed.And when aggregation failed, the court and the parties did not return to the task of handling the cases on an individual basis, Robreno said. “This stage of litigation led some litigants to refer to MDL875 as a 'black hole,' where cases disappeared forever from the active dockets of the court,” he wrote.

While, “as a matter of judicial culture, remanding cases is viewed as an acknowledgment that the MDL judge has failed to resolve the case, by adjudication or settlement, during the MDL process,” Robreno said he turned away from that mindset and set a “rigorous schedule” for hearing summary judgment motions and issuing decisions.

Due to bankruptcies by the companies that made asbestos, litigation has shifted to bankruptcy courts and to the makers and suppliers of components that contained asbestos, including manufacturers or suppliers of brakes, turbines and packing. “In sum, the time between the filing of motions for summary judgment and the panel's issuing a remand order was 74 days,” he said.

More than 600 cases have been remanded to 59 districts. Most of those cases resolved without the need for a trial on the merits.

There also is an issue of fraud in asbestos fraud, Robreno said, with doctors acting as litigation consultants and making positive findings “often upwards of 50% and in some studies as high as 90%, suggesting that the readings may not be neutral or legitimate.”

Sixth Circuit Rules Generic Drug Claims Preempted Under U.S. Supreme Court Precedent

The Sixth Circuit has ruled that state-law tort claims against generic drugmakers are federally pre-empted, according to Squire Sanders' Sixth Circuit blog. The Sixth Circuit majority cited Supreme Court precedent: PLIVA, Inc. v. Mensing and Mutual Pharmaceutical Co. v. Bartlett.  The majority also "reads those cases as broadly holding that state law failure-to-warn claims based on generic drugs are preempted by the FDA’s requirement that the labels on generic drugs conform to the labels on the brand-name drugs," according to the blog.

Philadelphia's Lull in Mass Torts Continues (But Out-of-State Drug Plaintiffs Tick Up 5%)

The Legal Intelligencer (my journalism alma mater) reports on the continuing trend of the reduction in mass torts in the Philadelphia court system. Court leaders, however, have seen a 5% uptick in filings by out-of-state plaintiffs suing over the pharmaceutical drugs they took.

One attorney told The Legal that more vigorous regulation by the Obama administration may have led to fewer tort lawsuits. "Obama has been more proactive in putting out more label changes, warning physicians about the side effects of prescription drugs. That takes away a lot of the failure-to-warn claims," plaintiffs attorney Sol Weiss said.
 

Pages

Subscribe to RSS - products liability